The gold standard for peptide therapy monitoring
The short answer
Peptide Therapy Monitoring Panel bundles 19 tests — IGF-1 (Insulin-like Growth Factor), TSH (Thyroid Stimulating Hormone) and Comprehensive Metabolic Panel plus 16 more — for $259.99 at Quest or $369.99 at Labcorp plus one $6 lab processing fee (from about $13.68 per test). Fast 8–12 hours before the draw; results post in 2–4 business days. Physician-authorized with no doctor's visit or insurance needed; one draw at Quest or Labcorp.
Other Labs
Starting at $500
+ lab fees
TestWell
$259.99
+ $6 lab processing fee
The Standardized Peptide Panel is designed for patients undergoing peptide therapy (BPC-157, GHK-Cu, Thymosin, CJC/Ipamorelin, and others). It combines 53 biomarkers across 19 targeted tests that clinicians use to monitor peptide therapy efficacy and safety. IGF-1 tracks growth hormone axis response — the primary marker for GH-releasing peptides. A full thyroid panel (TSH, Free T3, Free T4) catches thyroid shifts. Testosterone (Free & Total) plus SHBG together give the true bioavailable testosterone picture (Total alone is misleading without knowing how much is bound). Estradiol, DHEA-S, and Cortisol assess the rest of the hormonal landscape. CMP, CBC, and a Lipid Panel monitor metabolic and organ health. HbA1c and Insulin evaluate glucose metabolism, which peptides like CJC-1295 can influence. hs-CRP tracks systemic inflammation. Ferritin, Iron, and Vitamin B12 ensure nutrient status supports therapy. Vitamin D rounds out the picture as a co-factor for immune and hormonal function. Recommended at baseline, 4–6 weeks into therapy, then quarterly.
Baseline and periodic monitoring for peptide therapy — GH-releasing peptides (CJC-1295, ipamorelin, sermorelin, MK-677), BPC-157, and multi-peptide stacks. IGF-1 tracks the growth-hormone axis (the primary efficacy marker for GH peptides); a full thyroid panel, Testosterone with SHBG, estradiol, DHEA-S, and cortisol map the hormonal landscape; CMP, CBC, lipids, A1c, and fasting insulin cover organ and metabolic safety; hs-CRP tracks inflammation. Measures the body's response to a protocol — not the contents of a peptide vial.
Anyone on or starting peptide therapy who wants objective safety and efficacy data — especially GH-peptide users tracking IGF-1, people establishing a pre-protocol baseline, and those sourcing peptides without clinical oversight for whom independent monitoring is the only safety net. Not a substitute for a prescriber; abnormal results are a prompt to involve a clinician.
Sample Type
Blood draw
Fasting
Required
Results In
2–4 business days · typical; varies by lab and draw day
Biomarkers
52 across 19 tests
19 individual tests · 52 biomarkers measured — each test linked so you can learn more.
Fasting for 10–12 hours is required. Morning blood draw (before 10 AM) is preferred for accurate cortisol and hormone levels. Water is okay. If on injectable peptides, draw blood at trough (before next dose) for most accurate baseline.
What can throw off this result
Physician-reviewed “Before your test” pages — what each factor does, for how long, and what to do about it.
The short answer
Worth it if you're on peptide therapy — GH-releasing peptides (CJC-1295, ipamorelin, sermorelin, MK-677), BPC-157, or a multi-peptide stack — and want objective proof it's safe and working. It bundles the 53 biomarkers peptide users actually track, including IGF-1 (the key efficacy marker for GH peptides) and SHBG for accurate free-testosterone reading, into one draw at roughly half the à la carte cost. It monitors YOUR body's response — it does not test the peptide vial's contents.
We would rather you order the right test than the most expensive one.
A fasting morning draw (10-12 hours, water okay) at Quest or Labcorp, or at-home phlebotomy where available. If you're on injectable peptides, draw at trough — right before your next dose — for a consistent, comparable baseline. Cortisol and hormones read most accurately before 10 AM.
The markers that matter most and what an out-of-range value can mean. Reference ranges vary by lab, age and sex.
| Marker | Typical range | What it means |
|---|---|---|
| IGF-1 | Age/sex-specific range | The primary efficacy marker for GH-releasing peptides — the stable downstream signal of growth-hormone activity. If it isn't rising on a GH peptide, the protocol (or the product) isn't doing much. Very high levels warrant a clinician conversation. |
| Fasting glucose + insulin + HbA1c | Glucose 70-99 mg/dL; A1c <5.7% | GH-axis stimulation can raise blood sugar and insulin over time. Watching these catches a drift toward insulin resistance early, while it's easy to address. |
| Testosterone (Free & Total) + SHBG | Sex-specific ranges | Total testosterone alone is misleading without SHBG, which determines how much is bioavailable. Together they give the true free-testosterone picture peptide and hormone users need. |
| CMP + CBC + hs-CRP | Within lab reference ranges | The safety backbone: liver and kidney function, blood counts, and systemic inflammation. Any drift here is the signal to pause and get evaluated rather than push through. |
This section medically reviewed by Youmna DiStefano, MD — updated July 2026. General health information, not medical advice; interpret results with a qualified clinician.
A Peptide Therapy Monitoring Panel costs $259.99 at TestWell for a draw at Quest and $369.99 for a draw at Labcorp — $265.99 or $375.99 all-in, since the $6 lab processing fee is charged once per order and there is no draw or physician fee. With insurance you pay your plan's negotiated rate against your deductible; TestWell's price is fixed before the draw and HSA/FSA-eligible.
| Where you order | Price | One test, all-in | Notes |
|---|---|---|---|
| TestWell (drawn at Quest) | $259.99 | $265.99 | Includes the one $6 lab processing fee, charged once per order |
| TestWell (drawn at Labcorp) | $369.99 | $375.99 | This test is priced separately for a Labcorp draw; same order, same portal, same physician review, same one $6 fee |
| TestWell (drawn at BioReference — New York & New Jersey) | $369.99 | $375.99 | New York and New Jersey orders route to BioReference; Quest Health and Labcorp OnDemand don't take self-ordered draws in those states |
Competitor prices are read from the linked public pages and re-checked regularly; the labs' sites may add taxes or change prices without notice.
Compare more: Quest Diagnostics price list · Labcorp price list · Quest vs Labcorp · Lab test price checker
Your body's response — IGF-1, hormones, metabolic and organ markers. It cannot verify the identity, purity, or concentration of what's in a vial; that's a chemical assay (mass spec / HPLC) from a substance-testing lab, not a medical blood test. See the peptide therapy bloodwork guide for the full distinction.
It's built for GH-releasing peptides (CJC-1295, ipamorelin, sermorelin, MK-677), BPC-157 and repair peptides, and hormone-adjacent stacks. IGF-1 is the standout efficacy marker for the GH group. If you're only on a GLP-1 for weight loss, the GLP-1 Monitoring panel is purpose-built and cheaper — see the GLP-1 lab monitoring guide.
For injectable peptides, draw at trough — right before your next scheduled dose — so results are comparable over time. Fast 10-12 hours (water is fine) and aim for a morning draw before 10 AM for accurate cortisol and hormone levels. A baseline before you start is the single most valuable draw.
Many research peptides, including BPC-157, are not FDA-approved for general human use and have limited human safety data — so no one can promise they're safe for you. Bloodwork can't change that, but it's the practical harm-reduction tool: baseline and periodic organ, blood, and inflammation markers catch problems early. There's no test that measures BPC-157 itself — see the BPC-157 bloodwork guide.
The standard cadence is baseline (before starting), a follow-up at 4-6 weeks, then quarterly for as long as you're on the protocol. Because peptide therapy is ongoing, monitoring is ongoing — many users set up a recurring quarterly plan so the retest happens automatically rather than being remembered.
$259.99 at Quest or $369.99 at Labcorp for all 53 biomarkers (19 tests), plus one $6 lab processing fee per order. Ordered one at a time, the same tests come to $481.61 at Quest or $628.81 at Labcorp. HSA/FSA eligible, no doctor's visit or referral needed.
Your body. It measures how your physiology is responding to a peptide — IGF-1, hormones, metabolic and organ markers. It cannot verify the identity, purity, or concentration of what's in a vial; that's analytical chemistry from a substance-testing lab, not a medical blood test.
For injectable peptides, draw at trough — right before your next scheduled dose — so every draw is comparable over time. Fast 10-12 hours (water is fine) and aim for a morning draw before 10 AM for accurate cortisol and hormone levels.
The Peptide Therapy Monitoring Panel is built for GH-releasing peptides, BPC-157, and hormone-adjacent stacks — it leads with IGF-1 and a full hormone workup. The GLP-1 Monitoring panel is purpose-built for semaglutide/tirzepatide weight-loss therapy and is cheaper if that's all you're on. Choose by what you're actually taking.
TestWell takes no position on how you obtain peptides, and many research peptides aren't FDA-approved for general human use. What's true regardless: the less clinical oversight your source comes with, the more valuable independent monitoring is — baseline and quarterly bloodwork is how you catch a problem before it's serious. Every result is physician-reviewed.
Peptide Therapy Monitoring Panel results are typically ready in 2–4 business days after your draw at Quest or Labcorp. TestWell emails you the moment they post, and your results dashboard shows each marker against its reference range with a plain-English explanation.
Yes. Fasting for 10–12 hours is required. Morning blood draw (before 10 AM) is preferred for accurate cortisol and hormone levels. Water is okay. If on injectable peptides, draw blood at trough (before next dose) for most accurate baseline. The fasting before blood work guide covers how long to fast, what you can drink, and which results eating changes.
Oral contraceptives and estrogen and smoking and nicotine can change a Peptide Therapy Monitoring Panel result without anything being wrong. Oral contraceptives and estrogen can raise SHBG and Free T3 and 4 more markers on this test and can lower DHEA-Sulfate and Estradiol — expected; interpret testosterone with it. Smoking and nicotine can raise RBC and WBC and 3 more markers on this test and can lower HDL Cholesterol and 25-Hydroxy Vitamin D — tell the clinician; a high hematocrit in a smoker is usually smoking, not polycythemia. Each is explained on our physician-reviewed "Before your test" pages; when one applies, remove it and retest.
Yes. Laboratory tests are a qualified medical expense under IRS Publication 502, so the Peptide Therapy Monitoring Panel ($259.99 at Quest or $369.99 at Labcorp plus the $6 per-order lab fee) can be paid with an HSA or FSA debit card at checkout, or reimbursed from the itemized receipt in your TestWell account. For a health FSA the expense counts on the day your blood is drawn, which matters at the December 31 plan-year deadline.
Medically reviewed by Youmna DiStefano, MD · Last reviewed September 2026
Related guide
BPC-157 and Bloodwork: What Labs Can (and Can't) Tell You
Related guide
Peptide Therapy Bloodwork: What to Test for Safety and Results
Starting at $500 at other labs
TestWell Price
$259.99
+ $6 lab processing fee at checkout
No insurance needed · HIPAA compliant
Individual tests that complement this panel
Peptide Therapy Monitoring Panel
$259.99